

# The Next Frontier: Head and Neck Cancer Immunoprevention

J. Silvio Gutkind<sup>1</sup> and Jack D. Bui<sup>2</sup>



## Abstract

Restoring T cell–mediated antitumor immunity by targeting immune checkpoint inhibitors in head and neck squamous cell carcinoma (HNSCC) results in immunomodulation and durable remissions. However, the overall response rate to these immunotherapies in HNSCC is only approximately 20%. This raises the possibility that immunologic intervention earlier in the HNSCC continuum, such as in oral premalignant lesions (OPL) could

elicit an increased therapeutic response. New experimental studies suggest that immune therapies can be used for HNSCC prevention rather than therapy. Given the current excitement for precision medicine, these findings support the future development of multimodality approaches for preventive immune oncology. *Cancer Prev Res*; 10(12); 681–3. ©2017 AACR.

See related article by Jin Wang, et al., p. 684

## Oral Premalignancy and Chemoprevention

Every year, more than 600,000 cases of head and neck squamous cell carcinomas (HNSCC) are diagnosed worldwide. Pre-invasive tissue histologic abnormalities, such as dysplasia, often represent early to intermediate stages of the carcinogenic process during HNSCC progression. At a macroscopic level, these pre-invasive changes present as oral premalignant lesions (OPL), leukoplakia or erythroplakia (white or red patches, respectively) that have variable rates of progression to HNSCC. Unfortunately, there are still no effective therapeutic options to halt the progression of OPLs into HNSCC. To address this clinical need, our laboratory has developed a series of chemically induced oral carcinogenesis models by optimizing the delivery of a tobacco-mimetic, 4NQO, in the drinking water of C57Bl6 mice (1). This model recapitulates HNSCC progression, including the presence of easily recognizable OPLs. Using this model system, we have recently shown that the administration of metformin, the most widely used antidiabetic drug, reduces >90% the conversion of OPLs into HNSCC (1). This led to a currently open clinical trial evaluating the chemopreventive efficacy of metformin in patients with OPLs (NCT02581137).

## HNSCC and Immunotherapies

Recent breakthrough discoveries have highlighted the importance of the tumor microenvironment and its associated immune cells in cancer development and therapeutic resistance. For example, HNSCCs deploy multiple mechanisms to avoid immune

recognition and an antitumor immune response, including the recruitment of myeloid-derived suppressor cells and conditioning of the surrounding microenvironment to become highly immunosuppressive by expressing cytokines, such as IL6, IL10, and TGFβ, leading to the accumulation of suppressive regulatory T cells and the polarization of macrophages toward an immunosuppressive (M2) tumor-associated macrophage phenotype (2). A key emerging mechanism of tumor immunosuppression involves T-cell exhaustion, whereby T-cell reactivity is impaired due to activation of T-cell checkpoints, including PD-1, by its ligand, PD-L1 that is expressed by macrophages and some HNSCC cells restraining T-cell activation. Together, these conditions contribute to the suppression of cytotoxic CD8<sup>+</sup> T lymphocyte recruitment, survival, and function, and ultimately to the loss of an effective antitumor immune response. Indeed, recent revolutionary therapeutic strategies restoring T cell–mediated antitumor immunity in HNSCC by targeting immune checkpoint inhibitors, such as PD-L1 and PD-1, demonstrated immunomodulation and durable remissions (3, 4). This led to the recent approval by the FDA of anti–PD-1 antibodies, nivolumab and pembrolizumab, for HNSCC treatment. However, the overall response rate to these immunotherapies in HNSCC is only approximately 20% (3, 4). Moreover, whether PD-L1/PD-1 acts at the OPL stage to inhibit antitumor immunity is not known.

## HNSCC Immunoprevention


Unfortunately, we cannot yet predict which HNSCC patients will respond best to these immune oncology agents, and we still do not know whether immunologic intervention earlier in the HNSCC continuum, such as the premalignant state or early HNSCC lesions, could elicit an increased therapeutic response. In this regard, a study in this issue of *Cancer Prevention Research* has begun to address the impact of treating mice harboring 4NQO-induced OPLs with anti–PD-1 inhibitors (5). Caulin and colleagues provide exciting evidence that PD-1 blockade significantly diminishes the progression of low-grade oral SCC lesions into high-grade lesions. In this case, the authors have used heterozygous *Tp53*<sup>-/+</sup> mice to accelerate OPL development in response to 4NQO. Although this approach may have skewed the mutational

<sup>1</sup>Department of Pharmacology, Moores Cancer Center, University of California, San Diego, California. <sup>2</sup>Department of Pathology, Moores Cancer Center, University of California, San Diego, California.

**Corresponding Authors:** J. Silvio Gutkind, University of California, San Diego, 3855 Health Sciences Drive, #0803, La Jolla, California 92093. Phone/Fax: 858-534-5980; E-mail: sgutkind@ucsd.edu; and Jack D. Bui, University of California, San Diego, 9500 Gilman Drive #0612, La Jolla, California 92093. Phone: 858-534-3890; E-mail: jbui@ucsd.edu

doi: 10.1158/1940-6207.CAPR-17-0331

©2017 American Association for Cancer Research.

**Precision Immunoprevention****Figure 1.**

During the progression of the normal oral epithelium to head and neck squamous cell carcinoma (HNSCC), preinvasive tissue histologic abnormalities, such as low- and high-grade dysplasia, often represent early to intermediate stages of the carcinogenic process. At a macroscopic level, these preinvasive changes present as OPLs. New findings suggest that immunologic intervention with immune checkpoint inhibitors in OPL can prevent the progression of low-grade dysplasia to high-grade dysplasia, and likely to HNSCC. Given the current excitement for precision medicine, these findings support the future development of multimodality approaches as part of new preventive immune oncology strategies to halt HNSCC progression. These include the use of immune checkpoint inhibitors, cancer vaccines, and adjuvants that activate the innate immune system, such as TLR or STING agonists, alone and in combination, as well as combined with promising chemopreventive agents that have a beneficial impact in the tumor immune environment, such as metformin and COX inhibitors.

landscape of the emerging tumors, this possibility is mitigated by our recent sequencing of multiple 4NQO-induced tumors, which show *Tp53* mutations (unpublished observations) that may have been accelerated by the genetic deletion of one *Tp53* allele. They also observed a trend toward a decrease in the conversion of OPLs into HNSCC, which may need to be confirmed in larger groups of animals to achieve statistical significance.

The authors found that anti-PD-1 treatment increased the number of CD4<sup>+</sup>, CD8<sup>+</sup>, and FOXP3<sup>+</sup> T cells in low-grade lesions. Although the effect is slight, giving rise to on average a 2-fold increase in these populations, the findings were significant and certainly were correlated with prevention of cancer progression. The finding that FOXP3<sup>+</sup> cells were also increased suggests that the treatment overall increased infiltration of all types of T cells. It would be interesting to define the CD8<sup>+</sup>:FOXP3<sup>+</sup> ratio, as this has been well documented to correlate with productive antitumor immunity. This increase in T-cell infiltration correlated with increased production of known antitumor effector molecules, including IFN $\gamma$  and granzyme B, but not OX40 and 41BB, suggesting that CD8<sup>+</sup> cytotoxic activity was increased to a larger extent than conventional CD4<sup>+</sup> activity. These correlative immune signatures will need to be causally linked to the preventive effects of the anti-PD-1 therapy in future studies. Also, future studies could examine the role of PD-1<sup>+</sup> macrophages in this model system, given recent findings that PD-1 inhibits macrophage antitumor immune responses. Nevertheless, these findings suggest that controlling the infiltration and activity of T cells into premalignant lesions could emerge as effective strategies in the prevention of cancer. These findings provided the rationale for a recently launched HNSCC immune prevention trial (NCT02882282).

**Emerging Opportunities for Multimodality Precision Immunoprevention**

The authors' data also suggest that the fight against cancer could begin prior to transformation (Fig. 1) and could involve a broad

swath of patients. In this regard, the current excitement for neoantigen discovery, whether for use in therapeutic vaccination or in the generation of neopeptide specific T-cell therapy, represents a "holy grail" in precision immunology. It remains to be seen whether OPLs possess enough mutations to warrant a "preventive personalized vaccine." Even if OPLs have antigens, it is not clear that they are heavily infiltrated with immune cells. In this context, it is possible that the use of adjuvants that activate the innate immune system, such as TLR or STING agonists, could initiate immune responses in OPLs. For example, TLR7/8 ligands promote the recruitment and activation of innate immune cells and local antigen-presenting cells, leading to local accumulation of IFN $\gamma$  and induction of long-lasting adaptive immune responses against tumors (6). STING agonists can induce the production of type I IFNs and initiate self-sustaining immune responses (7). When considering the use of innate immune agonists in premalignancy, it will be important to consider the potential paradoxical tumor-promoting effects of innate cell activation. In fact, the activation of innate immune responses without antigen-specific immunity during carcinogenesis may promote an inflammatory milieu that hastens cancer progression (8). In this context, one may speculate that combining anti-PD-1 with TLR agonists at a premalignant stage may actually provide an optimal antitumor response. The increased accumulation of IFN $\gamma$  downstream of TLR activation would increase PD-L1 expression in the microenvironment, and thus, adding anti-PD-1 would overcome this suppressive effect.

Another exciting possibility is to combine anti-PD-1 therapy with metformin or cyclooxygenase (COX) inhibitors. Besides its impact on OPL cells, metformin suppresses the polarization of protumorigenic M2-like tumor-associated macrophages and protects CD8<sup>+</sup> tumor-infiltrating lymphocytes from functional exhaustion in the tumor microenvironment (9, 10). Classical COX inhibitors, including aspirin, have been recently shown to override the tumor-suppressive effect of the inflammatory mediator, PGE<sub>2</sub>, thereby synergizing with anti-PD-1 blockade in inducing the eradication of tumors (11). This raises the exciting

possibility of using metformin and/or COX inhibitors to boost the activity of immune checkpoint inhibitors, and to enhance the efficacy of anticancer prophylactic vaccines.

In summary, the authors' findings could be interpreted to represent the innovative use of immune therapy for prevention rather than therapy. In addition, given the current excitement for precision medicine, these findings provide a much-needed spark of enthusiasm for the development of multimodality approaches for preventive immune oncology.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### References

- Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. *Cancer Prev Res* 2012;5:562–73.
- Ferris RL. Immunology and immunotherapy of head and neck cancer. *J Clin Oncol* 2015;33:3293–304.
- Mehra RS, Seiwert TY, Mahipal A, Weiss J, Berger R, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012. *J Clin Oncol* 2016;34(suppl; abstr 6012).
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N Engl J Med* 2016;375:1856–67.
- Wang J, Xie T, Wang B, William WN, Heymach JV, El-Naggar AK, et al. PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions. *Cancer Prev Res* 2017;10:684–93.
- Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* 2013;14:1014–22.
- Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. *J Clin Invest* 2016;126:2404–11.
- Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? *Curr Opin Immunol* 2007;19:203–8.
- Ding L, Liang G, Yao Z, Zhang J, Liu R, Chen H, et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. *Oncotarget* 2015;6:36441–55.
- Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. *Proc Natl Acad Sci U S A* 2015;112:1809–14.
- Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. *Cell* 2015;162:1257–70.

#### Acknowledgments

The authors thank Dr. Zhiyong Wang and Michael Allevato for helping with the graphic used in this article.

#### Grant Support

J.S. Gutkind is supported by a grant from the NIH (DE026644). J.D. Bui is supported by grants from The Hartwell Foundation and the NIH (CA157885).

Received October 19, 2017; revised October 23, 2017; accepted October 23, 2017; published OnlineFirst November 14, 2017.

# Cancer Prevention Research

## The Next Frontier: Head and Neck Cancer Immunoprevention

J. Silvio Gutkind and Jack D. Bui

*Cancer Prev Res* 2017;10:681-683. Published OnlineFirst November 14, 2017.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1940-6207.CAPR-17-0331](https://doi.org/10.1158/1940-6207.CAPR-17-0331)

**Cited articles** This article cites 10 articles, 4 of which you can access for free at:  
<http://cancerpreventionresearch.aacrjournals.org/content/10/12/681.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/10/12/681>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.